Drug Trial Radar · NCT02855892
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
Last checked: Nov 19, 2026Latest source record: Mar 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Oct 2015
Primary completion
Oct 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- GemVax & KaelIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed as a randomized, placebo-controlled, single-blind, parallel design, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. Eligible subjects are randomized into a group out of the three study groups and a placebo group after four weeks of placebo run-in period. Placebo run-in period is concurrently proceeded as a wash-out period for previous treatment of benign prostatic hyperplasia, and a placebo is administered intradermally twice with two-week interval during this period. After that, the randomized subjects receive a study drug and a placebo intradermally seven times with two-week interval by visiting at Week 0, 2, 4, 6, 8, 10, and 12. After the treatment period, the subjects additionally visit at Week 13 and 16, and the efficacy is evaluated at Week 4, 8, 12, 13, and 16, and the safety is evaluated over the 16-week period.
Conditions
- Benign Prostatic Hyperplasia (BPH)
Interventions
PlaceboOther
GV1001Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of doses of GV1001 by comparing the level of change in IPSS scores in three study groups to a control group.Time frame: at Week 0, 4, 8, 12, 13, and 16
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Inje University Busan Paik Hospital
Busan, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
Chung-ang University Hospital
Seoul, South Korea
Eulji General Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Hanyang University Guri Hospital
Guri-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Dongguk University Gyeongju Hospital
Gyeongju, Gyeongsangbuk-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.